The Zhitong Finance App learned that Kangfang Biotech (09926) rose more than 10% in early trading. As of press release, it rose 9.25% to HK$99.2, with a turnover of HK$625 million.

According to the news, on September 3, Kang Fang Biotech announced that the first-line treatment for PD-L1 positive (TPS ≥ 1%) advanced non-small cell lung cancer (NSCLC) with evosimab head-to-head with K drugs reached a critical secondary OS endpoint and obtained positive results with statistically significant clinical benefits. Up to now, Evosi has obtained positive OS and PFS results in multiple global phase III clinical trials of head-to-head comparison of PD-1/L1 treatments, and is expected to leverage the existing market pattern with better efficacy in the future.

According to public information, pabolizumab is the most representative drug that started the 1.0 era of tumor immunotherapy, promoted significant progress in lung cancer treatment, and became one of the most successful innovative drugs commercialized globally. On the basis of pabolizumab, evosil further enabled patients to achieve significant benefits, demonstrating the breakthrough clinical value and huge commercial value potential of evosil as the cornerstone drug of the next generation of tumor immunity.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.